Last reviewed · How we verify
SEA-CD40
At a glance
| Generic name | SEA-CD40 |
|---|---|
| Sponsor | Seagen Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of SEA-CD40 Given With Other Drugs in Cancers (PHASE2)
- Safety Study of SEA-CD40 in Cancer Patients (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SEA-CD40 CI brief — competitive landscape report
- SEA-CD40 updates RSS · CI watch RSS
- Seagen Inc. portfolio CI